Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Other Accumulated Expenses (2021 - 2026)

Climb Bio filings provide 6 years of Other Accumulated Expenses readings, the most recent being $113000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 88.7% to $113000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $113000.0 through Mar 2026, down 88.7% year-over-year, with the annual reading at $59000.0 for FY2025, 33.71% down from the prior year.
  • Other Accumulated Expenses hit $113000.0 in Q1 2026 for Climb Bio, up from $59000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.0 million in Q1 2025 and bottomed at $22000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $210454.5, with a median of $113000.0 recorded in 2026.
  • The largest annual shift saw Other Accumulated Expenses surged 250.0% in 2025 before it plummeted 88.7% in 2026.
  • Climb Bio's Other Accumulated Expenses stood at $245000.0 in 2022, then tumbled by 43.67% to $138000.0 in 2023, then crashed by 35.51% to $89000.0 in 2024, then tumbled by 33.71% to $59000.0 in 2025, then soared by 91.53% to $113000.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Other Accumulated Expenses are $113000.0 (Q1 2026), $59000.0 (Q4 2025), and $77000.0 (Q3 2025).